Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
← catalyst calendarNCT05099770 · readout ≤ 1,230 d
Sponsored by Prokidney (industry) · PROK — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
685estimated
Sites
88
Countries
Mexico, Puerto Rico, Taiwan +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-01-05 | actual | When the study began enrolling |
| Primary completion | Dec 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2021-10-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Type 2 Diabetes Mellitus
- Chronic Kidney Diseases
Interventions
- Biological: Renal Autologous Cell Therapy (REACT/ rilparencel)
- Procedure: Sham Comparator
Primary outcomes
what the primary-completion date above is the date OFSurrogate / Intermediate Efficacy Endpoint -eGFR Slope
measured 18 months after the 135th participant receives their first injection / sham.
Clinical Endpoint
measured From date of first injection until the date of first event: 40% reduction in eGFR, eGFR < 15 mL/min/1.73m² and/or chronic dialysis, and or renal transplant or date of renal or cardiovascular death, whichever came first, assessed up to 94 months.
Publications
- PMID 41481370 — linked by the registry
- PMID 40333016 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PROK's whole pipeline · Catalyst calendar · Every registered study · What changed